Controlling the drug-resistant tuberculosis epidemic in India: challenges and implications

被引:9
作者
Husain, Aliabbas A. [1 ]
Kupz, Andreas [2 ]
Kashyap, Rajpal S. [1 ]
机构
[1] DR GM Taori Cent India Inst Med Sci CIIMS, Res Ctr, 88-2 Bajaj Nagar, Nagpur 440010, Maharashtra, India
[2] James Cook Univ, Ctr Mol Therapeut, Australian Inst Trop Hlth & Med, Cairns, Australia
关键词
Tuberculosis; India; Drug resistance; Diagnosis; Epidemics;
D O I
10.4178/epih.e2021022
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
India has a higher tuberculosis (TB) burden than any other country, accounting for an estimated one-fourth of the global burden. Drug-resistant tuberculosis (DR-TB) presents a major public health problem in India. Patients with DR-TB often require profound changes in their drug regimens, which are invariably linked to poor treatment adherence and sub-optimal treatment outcomes compared to drug-sensitive TB. The challenge of addressing DR-TB is critical for India, as India contributes over 27% of global DR-TB cases. In recent decades, India has been proactive in its battle against TB, even implementing a revised National Strategic Plan to eliminate TB by 2025. However, to achieve this ambitious goal, the country will need to take a multifaceted approach with respect to its management of DR-TB. Despite concerted efforts made by the National TB Elimination Program, India faces substantial challenges with regard to DR-TB care, especially in peripheral and resource-limited endemic zones. This article describes some of the major challenges associated with mitigating the growing DR:TB epidemic in India and their implications.
引用
收藏
页数:9
相关论文
共 30 条
[1]   Drug-resistance profiling and transmission dynamics of multidrug-resistant Mycobacterium tuberculosis in Saudi Arabia revealed by whole genome sequencing [J].
Al-Ghafli, Hawra ;
Kohl, Thomas A. ;
Merker, Matthias ;
Varghese, Bright ;
Halees, Anason ;
Niemann, Stefan ;
Al-Hajoj, Sahal .
INFECTION AND DRUG RESISTANCE, 2018, 11 :2219-2229
[2]  
[Anonymous], 2016, USE MOL LINE PROBE A
[3]  
[Anonymous], Definitions and reporting framework for tuberculosis 2013 revision
[4]   The number of privately treated tuberculosis cases in India: an estimation from drug sales data [J].
Arinaminpathy, Nimalan ;
Batra, Deepak ;
Khaparde, Sunil ;
Vualnam, Thongsuanmung ;
Maheshwari, Nilesh ;
Sharma, Lokesh ;
Nair, Sreenivas A. ;
Dewan, Puneet .
LANCET INFECTIOUS DISEASES, 2016, 16 (11) :1255-1260
[5]   Xpert MTB/XDR: a 10-Color Reflex Assay Suitable for Point-of-are Settings To Detect Isoniazid, Fluoroquinolone, and Second-Line-Injectable-Drug Resistance Directly from Mycobacterium tuberculosis-Positive Sputum [J].
Cao, Yuan ;
Parmar, Heta ;
Gaur, Rajiv L. ;
Lieu, Deanna ;
Raghunath, Shobana ;
Via, Nova ;
Battaglia, Simone ;
Cirillo, Daniela M. ;
Denkinger, Claudia ;
Georghiou, Sophia ;
Kwiatkowski, Robert ;
Persing, David ;
Alland, David ;
Chakravorty, Soumitesh .
JOURNAL OF CLINICAL MICROBIOLOGY, 2021, 59 (03)
[6]  
Central TB Division Ministry of Health and Family Welfare, IND TB REP 2020 NAT
[7]   Drug-resistant tuberculosis: is India ready for the challenge? [J].
Chatterjee, Soumya ;
Poonawala, Husain ;
Jain, Yogesh .
BMJ GLOBAL HEALTH, 2018, 3 (04)
[8]  
Chaudhuri A, 2020, J Assoc Chest Phys, V8, P53, DOI [10.4103/JACP.JACP_47_20, DOI 10.4103/JACP.JACP_47_20]
[9]   Whole-Genome Sequencing To Guide the Selection of Treatment for Drug-Resistant Tuberculosis [J].
Dookie, Navisha ;
Naidoo, Kogieleum ;
Padayatchi, Nesri .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (08)
[10]  
Dorman SE, 2018, LANCET INFECT DIS, V18, P76, DOI [10.1016/S1473-3099(17)30691-6, 10.1016/s1473-3099(17)30691-6]